Haanen JBAG - Search Results

1

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.

van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van Breeschoten J, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: haanen jbag. Ann Intern Med. 2021 May;174(5):641-648. doi: 10.7326/M20-3419. Epub 2021 Feb 16. Ann Intern Med. 2021. PMID: 33587686

2

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ. Haanen JB, et al. Cancer Immunol Immunother. 2006 Apr;55(4):451-8. doi: 10.1007/s00262-005-0018-5. Epub 2005 Jul 21. Cancer Immunol Immunother. 2006. PMID: 16034562 Free PMC article. Clinical Trial.

3

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. de Mulder PH, et al. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Ned Tijdschr Geneeskd. 2008. PMID: 18380383 Review. Dutch.

4

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E. van der Veldt AA, et al. Clin Cancer Res. 2008 Apr 15;14(8):2431-6. doi: 10.1158/1078-0432.CCR-07-4089. Clin Cancer Res. 2008. PMID: 18413834

5

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB. van der Veldt AA, et al. Br J Cancer. 2008 Jul 22;99(2):259-65. doi: 10.1038/sj.bjc.6604456. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594533 Free PMC article. Clinical Trial.

6

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.

van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD. van Cruijsen H, et al. Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656. Clin Cancer Res. 2008. PMID: 18794101

7

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Bex A, et al. World J Urol. 2009 Aug;27(4):533-9. doi: 10.1007/s00345-008-0368-7. Epub 2009 Jan 15. World J Urol. 2009. PMID: 19145434

8

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN. Hadrup SR, et al. Nat Methods. 2009 Jul;6(7):520-6. doi: 10.1038/nmeth.1345. Epub 2009 Jun 21. Nat Methods. 2009. PMID: 19543285

9

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. van Erp NP, et al. J Clin Oncol. 2009 Sep 10;27(26):4406-12. doi: 10.1200/JCO.2008.21.7679. Epub 2009 Aug 10. J Clin Oncol. 2009. PMID: 19667267

10

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Bex A, et al. Acta Oncol. 2010 May;49(4):520-3. doi: 10.3109/02841860903521111. Acta Oncol. 2010. PMID: 20105087 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

430 results

Search Page